Related Experiment Videos

Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation

M Murata1, Y Matsubara, K Kawano

  • 1Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.

Circulation
|December 13, 1997
PubMed

Insights

Genetic variations in platelet glycoprotein (GP) Ib alpha may increase the risk of coronary artery disease (CAD) in younger individuals. The Met allele of GP Ib alpha is associated with both the prevalence and severity of CAD in those under 60.

Area of Science:

  • Cardiovascular Genetics
  • Platelet Biology
  • Thrombosis Research

Background:

  • Platelets are crucial in coronary thrombosis, with antiplatelet therapies common for coronary artery disease (CAD).
  • Genetic factors influencing platelet function in CAD remain largely unexplored.
  • The glycoprotein (GP) Ib/IX complex, a von Willebrand factor receptor, mediates platelet activation under shear stress.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in the GP Ib alpha receptor and the prevalence and severity of CAD.
  • To determine if specific GP Ib alpha genotypes are risk factors for CAD in different age groups.

Main Methods:

  • Genotyping of GP Ib alpha (145Thr/Met polymorphism and variable number of tandem repeats) was performed.
  • Study included 91 patients with confirmed CAD (myocardial infarction or angina) and 105 healthy controls.
  • Coronary angiography was used to assess lesion severity (Gensini score).

Main Results:

  • The Thr/Met genotype frequency was significantly higher in CAD patients under 60 years old compared to controls (31.8% vs. 16.0%).
  • A significant association was found between the Thr/Met genotype and increased angiographic severity of CAD (Gensini score >= 40).
  • No significant differences in GP Ib alpha genotype distribution were observed between myocardial infarction and angina pectoris patients.

Conclusions:

  • The Met allele of GP Ib alpha appears to be a risk factor for CAD prevalence and severity in individuals aged 60 years or younger.
  • Further large-scale studies with incident cases are recommended to validate these findings.
Abstract

Related Concept Videos